Komori
JCR Pharmaceuticals (4552) · FactAnnual Impact Amount Updated

Adoption of the Revenue Recognition Standard

First written in FY2022-Q2. . Latest entry: FY2022.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2022-Q2 – FY20222021: 120212022: 22022
Same theme, other companies
Impact of Applying Revenue Recognition Accounting Standards on Financial StatementsA theme 366 companies write about · 218 as a headwind · 11 as a tailwind

83 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 366 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022Annual Impact Amount UpdatedAnnual report

    「As a result, net sales for the consolidated fiscal year increased by ¥57 million, cost of sales increased by ¥280 million and selling, general and administrative expenses decreased by ¥223 million, while operating income, ordinary income and profit before income taxes and other adjustments for the year were unaffected.」

    The annual application of the Revenue Recognition Standard and related standards increased net sales by ¥57 million and cost of sales by ¥280 million and decreased selling, general and administrative expenses by ¥223 million, while there was no impact on operating income or related items.
  2. FY2022-Q3Update to the cumulative first 3-quarter impact amountsAnnual report

    「As a result, net sales for the cumulative third quarter consolidated accounting period increased by ¥42 million, cost of sales increased by ¥223 million and selling, general and administrative expenses decreased by ¥181 million, while operating income, ordinary income and profit before income taxes and other adjustments for the quarter were unaffected. There was also no impact on the beginning balance of retained earnings.」

    The presentation impact amounts for the cumulative first 3 quarters arising from the application of the Revenue Recognition Standard and related standards were updated. Net sales increased by ¥42 million, cost of sales increased by ¥223 million and selling, general and administrative expenses decreased by ¥181 million, while there was no impact on operating income or related items.
  3. FY2022-Q2First statedAnnual report

    「The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020; hereinafter, the "Revenue Recognition Standard") and related standards were applied from the beginning of the first quarter consolidated accounting period. Revenue is recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The Revenue Recognition Standard and related standards were applied from the beginning of the first quarter of fiscal 2021. Net sales increased by ¥29 million, cost of sales increased by ¥152 million and selling, general and administrative expenses decreased by ¥123 million, while there was no impact on operating income, ordinary income or profit before income taxes and other adjustments for the quarter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Adoption of the Revenue Recognition Standard | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori